Mixing COVID-19 vaccines only triggers mild and short-lived adverse reactions: A preliminary safety report
It has been proposed that immunization with different vaccine products for the first and second dose may increase the intensity and breadth of immune responses, while simplifying vaccine availability and delivery logistics.
The future of vaccines: nanoparticle vaccines could protect against present and future coronaviruses
Current mRNA vaccines may be a potent weapon against the most troublesome immune-evading SARS-CoV-2 variants.
How effective is the Pfizer-BioNTech vaccine at preventing SARS-CoV-2 infection?
As vaccines roll out, studies are underway to continue to monitor their efficacy against SARS-CoV-2 infection, and particularly, against asymptomatic infections.
Should you get the COVID-19 vaccine if you lack the cells that make antibodies?
Multiple sclerosis (MS) is an autoimmune disorder that is often treated with drugs that deplete B cells and therefore interfere in the process of antibody production.
Added benefit: A single dose of COVID-19 vaccine can also protect your loved ones at home
Researchers from Public Health England followed COVID-19 vaccine recipients nationwide to measure their risk of infection and transmission.
Smiling while still wearing a mask and how to beat the pandemic blues
The COVID-19 pandemic is no joke. We get that. But at the same time, in highly stressful times, kindness, humour and courtesy can help us pull through.
Anti-vaccine misinformation poses a worldwide threat and international policymakers must take action: opinion
Despite the tremendous gains that the scientific community has made during this pandemic, there is still a major battle to fight: the battle against disinformation.
Promising news for pregnant women: take one shot and help two!
Findings in recent issues of JAMA Pediatrics and The New England Journal of Medicine suggest pregnant women are more likely to get severely ill from COVID-19 than women who are not pregnant.
The role of SARS-CoV-2 antibodies in protection against reinfection
A large, national, multicentre prospective cohort study of hospital healthcare workers in the UK (The SARS-CoV-2 Immunity and Reinfection Evaluation, SIREN) reports, in an interim analysis published in The Lancet, that participants who previously had SARS-CoV-2 antibodies had an 84% lower risk of (re)infection.